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fused together using bone (autograft) from patient’s hip, which
requires additional surgery and leads to increased co-morbidity,
blood loss, infection rate, and pelvic instability. We assessed the
cost-effectiveness of rhBMP-2 compared with autograft in spine
fusion surgery over two years from both a health care payer’s and
societal perspectives in The Netherlands. METHODS: An eco-
nomic model was developed to evaluate differences in results
between spine-fusion surgery with rhBMP-2 and fusion with
bone autograft. The cost and health-related quality-of-life asso-
ciated with both treatment options were estimated for two years
after surgery. Data were obtained from a previously published
analysis of pooled data, in which patients in the rhBMP-2 arm
showed signiﬁcant clinical improvements after surgery compared
to standard therapy. Costs were obtained according to the Dutch
costing manual, and are reported in 2007 values. RESULTS: In
The Netherlands, from the health care payer’s perspective, using
rhBMP-2 lead to extra cost of €1,520 per case, and incremental
cost-effectiveness ratio (ICER) of €27,260/QALY. Signiﬁcant
reduction in secondary interventions, and better fusion rates
associated with rhBMP-2 treatment resulted in faster return to
work and reduced productivity loss. CONCLUSIONS: The stan-
dard use of rhBMP-2 in ALIF surgery is a cost-effective treatment
option in The Netherlands from the payer’s perspective, and a
cost-saving option from the societal perspective.
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OBJECTIVES: Assess cost-effectiveness of 35 days rivaroxaban,
an oral direct Factor Xa inhibitor, versus subcutaneous enox-
aparin regimens for prevention of venous thromboembolism
(VTE) following total hip replacement (THR). METHODS:
Rivaroxaban regimens were compared with enoxaparin regimens
following THR in two large randomized controlled trials. In
RECORD1, patients received 35 days prophylaxis with rivaroxa-
ban or enoxaparin. In RECORD2, patients received 35 days
rivaroxaban or 12 days enoxaparin. In RECORD1, rivaroxaban
reduced total VTE (composite: any DVT, non-fatal PE, all-cause
mortality) by 70% versus enoxaparin after 35 days prophylaxis,
although the reduction in symptomatic VTE was not statistically
signiﬁcant. In RECORD2, 35 days rivaroxaban reduced total
VTE by 79% and symptomatic VTE by 80% versus 12 days
enoxaparin. A cost–utility model (health care perspective),
populated by the RECORD1-2 trials, assessed cost-effectiveness
of rivaroxaban versus both durations of enoxaparin over ﬁve
years. Risks of VTE and post-thrombotic syndrome beyond the
trial period were estimated from published data. Costs, in euros
(€), were derived from published Spanish sources. Utilities were
derived from published literature. Enoxaparin prophylaxis after
THR in Spain lasts approximately 27 days. Hence, in addition to
separate analyses based on RECORD1 and 2, RECORD1-2 data
were pooled to allow the cost-effectiveness of 35 days rivaroxa-
ban versus the Spanish enoxaparin duration to be estimated.
RESULTS: Thirty-ﬁve days rivaroxaban dominated 35 days
enoxaparin, with a small QALY gain and cost savings of €48.10
per patient. Rivaroxaban,was also cost-effective versus 12 days
enoxaparin (incremental cost per QALY, €3156). Rivaroxaban
remained dominant over enoxaparin when RECORD1-2 data
were combined (QALY gain, 0.011; cost savings per patient,
€12.24). Probabilistic sensitivity analyses showed rivaroxaban
dominating in 60% of cases and cost-effective in 100% (cost per
QALY; €20,000) CONCLUSIONS: Rivaroxaban is cost-
effective versus both 12 days and 35 days enoxaparin, for pre-
venting VTE following THR in Spain.
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OBJECTIVES: Assess cost-effectiveness of 35 days rivaroxaban,
an oral direct Factor Xa inhibitor, versus 12 days and 35 days
subcutaneous enoxaparin for prevention of venous throm-
boembolism (VTE) following total hip replacement (THR).
METHODS: Rivaroxaban regimens were compared with
enoxaparin regimens following THR in two large randomized
controlled trials. In RECORD1, patients received 35 days
prophylaxis with rivaroxaban or enoxaparin. In RECORD2,
patients received 35 days rivaroxaban or 12 days enoxaparin.
The duration of enoxaparin in RECORD1 represents the ACCP-
recommended duration of prophylaxis following THR, but in
Canada a shorter duration is often applied. In RECORD1, rivar-
oxaban reduced total VTE (composite: any DVT, non-fatal PE,
all-cause mortality) by 70% versus enoxaparin after 35 days
prophylaxis. The reduction in symptomatic VTE with rivaroxa-
ban was not statistically signiﬁcant and not included in the
model. In RECORD2, rivaroxaban reduced total VTE by 79%
and symptomatic VTE by 80% versus 12 days enoxaparin. A
cost–utility model (Ministry of Health perspective) assessed cost-
effectiveness of rivaroxaban versus both durations of enoxaparin
over ﬁve years. The model is populated by RECORD1-2 trials,
while published epidemiological and clinical data estimated the
risk of further VTE events and post-thrombotic syndrome
beyond the trial period. Costs were derived from published
Canadian sources and expressed in 2008 Canadian Dollars (C$).
Utilities were derived from published literature. Potential savings
from oral administration were also included. RESULTS: Thirty-
ﬁve days rivaroxaban dominated 35 days enoxaparin, with a
small QALY gain and savings of C$282.58 per patient. Cost
savings are driven mainly by reduced outpatient administration
costs. Probabilistic sensitivity analyses showed this dominance in
98% of cases. Rivaroxaban was also cost-effective versus 12 days
enoxaparin, with an incremental cost per QALY of C$33,323.
CONCLUSIONS: Rivaroxaban is cost-effective versus both 12
days and 35 days enoxaparin, for the prevention of VTE follow-
ing THA in Canada.
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OBJECTIVES: Assess cost-effectiveness of rivaroxaban, an oral
direct Factor Xa inhibitor, versus subcutaneous enoxaparin for
prevention of venous thromboembolism (VTE) following total
knee replacement (TKR) in the UK and Spain. METHODS:
RECORD3, a large randomized controlled trial, compared
VTE prophylaxis for 12 days with rivaroxaban versus 12 days
enoxaparin following TKR. Rivaroxaban reduced total VTE
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